Dimerix Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia.
Key Metrics
PE ratio
-
PB ratio
23.86
Dividend yield
-
Beta
0.22
Market cap
$315.21M
Enterprise value
$246.91M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://dimerix.com |
| Mailing address | 425 Smith Street Fitzroy VIC 3065 Australia |
| Phone / Fax | 1300 813 321 / 61 8 9388 8256 |
Dividends
More: Dimerix Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Dimerix paid $- dividend and the ex-dividend date was 24 Sep 1999.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.DXB dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Dimerix.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, Ph.D. | CEO, MD & Director | ||
| Mr. Robert Shepherd | Chief Operating Officer | ||
| Dr. David Everett Fuller BPharm, M.D., MBBS | Chief Medical Officer | 61 | |
| Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D. | CFO & Company Secretary | 58 | |
| Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D. | Chief Scientific Advisor |
Profitability and management effectiveness
Profit margin
-237.20%
Operating margin
-350.71%
Return on assets
-32.13%
Return on equity
-83.97%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Dimerix is 315.21M and its enterprise value is 246.91M. The enterprise value to revenue ratio of DXB is 44.20. The enterprise value to EBITDA ratio of DXB is -7.80.
The DXB's stocks Beta value is 0.22 making it 78% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Dimerix (DXB)
Dimerix (ASX:DXB) Frequently Asked Questions
1. What is Dimerix's Stock Symbol?
Dimerix trades on ASX under the ticker symbol "DXB".
2. What is Dimerix's stock price today?
One share of DXB stock can currently be purchased for approximately $0.525.
3. How can I contact Dimerix?
Dimerix's mailing address is 425 Smith Street Fitzroy VIC 3065 Australia. The company can be reached via phone at 1300 813 321.
4. What is Dimerix's official website?
The official website of Dimerix is https://dimerix.com.